In relation to World Sepsis Day and Sepsis Awareness Month we have decided to make a webinar on the biomarker calprotectin’s role in diagnosing and monitoring sepsis. Sepsis arises when the body’s response to an infection injures its own tissues and organs. If not recognised in an early phase and treated quickly, sepsis can lead to shock, multi-organ failure, and death [1]. Rapid and correct diagnosis is very important, as any delay in treatment increases mortality. Biomarkers can help in diagnosing, and calprotectin has shown to be a very promising early biomarker.
There are several recent studies which support calprotectin as a promising biomarker in sepsis [2-6]. In this webinar Gentian’s Product Manager for GCAL® Calprotectin Immunoassay, for plasma and serum, will present selected research on calprotectin and sepsis. Please watch the webinar here:
GCAL® - Gentian calprotectin immunoassay - early access to results
Calprotectin has potential applications for early detection and monitoring of sepsis. Gentian’s Calprotectin Immunoassay GCAL® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA), and is therefore rapidly performed in only 10 minutes, making it extra beneficial when it is critical to get fast access to the results.
Learn more about GCAL® - contact us now
Do you have questions about GCAL® or calprotectin as a biomarker send an email to marketing@gentian.com or fill out the form below:
References:
- www.global-sepsis-alliance.org/
- Fullerton et al. (2020). Meeting abstracts, Critical Care 2020, 24(Suppl 1):87
- Havelka et al. (2020). Sci Rep. 2020 Mar 6;10(1):4208
- Bartakova et al. (2019). Diagnostic Microbiol Infect Dis 93: 219-226
- Larsson et al. (2020). SJCLM Dec 2019, doi.org/10.1080/00365513.2019.1703216
- Parke et al. (2020). Meeting abstracts, Critical Care 2020, 24(Suppl 1):87
